TRDAEntrada Therapeutics, Inc.

Sign up free

Market reactionShares rose 13% on Nov 2.

IntactLast material event Nov 5, 2026

Entrada's higher-dose DMD cohorts report in 2027; first-dose dystrophin was small

Entrada Therapeutics develops exon-skipping medicines for Duchenne muscular dystrophy; ENTR-601-44 and ENTR-601-45 are in Phase 1/2 trials, and nothing is approved.

Entrada links exon-skipping oligonucleotides to a delivery vehicle meant to raise muscle uptake. At the first dose, ENTR-601-44 was well tolerated and improved Time to Rise velocity in most treated boys. ENTR-601-45 raised dystrophin only 0.10%, as the company expected at a low dose. The case depends on whether higher doses produce clearly more dystrophin and function. ENTR-601-44 data at 12 mg/kg come in the first quarter of 2027. Cash of $223 million lasts into the third quarter of 2027.

Thesis checklist

0 risks need attention

Select a row for evidence
Higher ENTR-601-44 dose raises dystrophinAwaiting evidenceNext: Cohort 2 dystrophin and function data.

Why it is in this state

The evidence, what would weaken it and the source filing

ENTR-601-45 builds on its first doseAwaiting evidenceNext: Cohort 2 data in the first half of 2027.

Why it is in this state

The evidence, what would weaken it and the source filing

Time to Rise benefit holds over timeSupportedNext: Cohort 1 open-label data.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash reaches the 2027 readoutsSupportedNext: Quarterly cash and any financing.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

ELEVATE-44-201 Cohort 2 data at 12 mg/kg

Tests: Higher ENTR-601-44 dose raises dystrophin

First quarter of 2027 (company)

Does doubling the ENTR-601-44 dose produce clearly more dystrophin and function without new safety problems?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentClinical
-6.4%Nov 5, 2026

Entrada's higher-dose DMD cohorts report in 2027; first-dose dystrophin was small

IntactClinical
-7.7%May 18, 2026

ENTR-601-44's Phase 1/2 efficacy signal in exon 44 DMD sets the thesis — dose escalation and regulatory pathway clarity will determine whether it translates to approval

IntactClinical
-57.3%May 7, 2026

ELEVATE-44-201 Cohort 1 positive data readout

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Duchenne muscular dystrophy· exon 44 skipping amenable
ENTR-601-44 · 3 upcoming · 2 completed
Phase 1/2 DataELEVATE-44-201
By end of 2026
Phase 1/2 DataELEVATE-44-201
Q1 2027
Phase 1/2 DataELEVATE-44-201
TBD
Inherited retinal disease
Ocular disease program · 1 upcoming
Second ocular clinical candidate nomination
H2 2026
Myotonic dystrophy type 1
VX-670 · 1 upcoming · 1 completed
Phase 1/2 Data: InterimGALILEO
H2 2026
Duchenne muscular dystrophy· exon 45 skipping amenable
ENTR-601-45 · 2 upcoming · 2 completed
Phase 1/2 DataELEVATE-45-201
H1 2027
Phase 1/2 DataELEVATE-45-201
TBD
Duchenne muscular dystrophy
ENTR-601-44 · 1 upcoming
Phase 1b Study InitiationELEVATE-44-102
TBD
Duchenne muscular dystrophy· exon 51 skipping amenable
ENTR-601-51 · 1 upcoming
Regulatory Submission
TBD
Duchenne muscular dystrophy· exon 50 skipping amenable
ENTR-601-50 · 1 upcoming · 1 completed
Study InitiationELEVATE-50-201
TBD
Inherited retinal disease
Retinal disease program · 1 completed
Retinal disease lead candidate nomination
Reported Jan 8, 2026

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Entrada Therapeutics (TRDA) investment thesis intact?
Yes. Readouts currently rates the Entrada Therapeutics Thesis Intact. Entrada's higher-dose DMD cohorts report in 2027; first-dose dystrophin was small.
What is the next catalyst for Entrada Therapeutics (TRDA)?
The next dated event is Phase 1/2 interim results (GALILEO) for VX-670, expected H2 2026, as stated by the company. Also ahead: Phase 1/2 results (ELEVATE-44-201) for ENTR-601-44, expected By end of 2026.
How long will Entrada Therapeutics' cash last?
Entrada Therapeutics has said its cash will fund operations into the fourth quarter of 2027 (guidance as of November 5, 2026). It reported $193 million in cash as of September 30, 2026.

Other companies we cover in these diseases

Disease areas: Eye diseases, Neuromuscular diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

7 peers tracked

For informational purposes only—not investment advice. Always conduct your own research before making investment decisions.

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.